Lamivudina + Zidovudina Accord (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside analogues that are phosphorylated inside cells to active triphosphate forms. These active metabolites compete with natural nucleosides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and blocking HIV replication.

The dosage of Lamivudina + Zidovudina Accord is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and the overall antiretroviral regimen. Patients should follow the exact dosing instructions provided by their clinician.

Safety in pregnancy and lactation has not been fully established. The drug may be used during pregnancy only when the potential benefits justify the potential risks to the fetus, and breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine and zidovudine belong to the nucleoside reverse transcriptase inhibitor class, offering a well‑characterised safety profile and extensive clinical experience. Compared with newer agents, they may have more frequent hematologic side effects but remain effective components of many established combination regimens.

Lamivudina + Zidovudina Accord should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Patients should swallow the dosage form whole and not crush or chew it unless specifically instructed.

Serious risks include lactic acidosis, severe hepatic steatosis, bone‑marrow suppression leading to pancytopenia, and hypersensitivity reactions such as rash or fever. Patients should be monitored regularly for these conditions and seek immediate medical attention if symptoms develop.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid this medication. It is also contraindicated in patients with severe bone‑marrow failure or uncontrolled liver disease, and caution is advised in pregnant or breastfeeding women.